Bio-Gene Technology

Bio-Gene Technology EBITDA Growth YoY

The Year-over-Year EBITDA Growth of Bio-Gene Technology (BGT.AX) as of Nov 22, 2026 is -12.61 %. In the previous year, Year-over-Year EBITDA Growth was -0.03 % — a change of 40,136.75% (lower).

EBITDA Growth YoY

-12.61 %

YoY

40,136.75%

Last updated:

Year-over-Year EBITDA Growth of Bio-Gene Technology is 2026 -12.61 % . Year-over-Year EBITDA Growth of Bio-Gene Technology was 2025 -0.03 % . It decreases by 40,136.75% lower compared to the previous year.

The Bio-Gene Technology EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2019
34.15 AUD
Jan 1, 2020
2.02 AUD
Jan 1, 2021
-20.99 AUD
Jan 1, 2022
-32.25 AUD
Jan 1, 2023
-6.49 AUD
Jan 1, 2024
15.59 AUD
Jan 1, 2025
-0.03 AUD
Jan 1, 2026
-12.61 AUD
The Bio-Gene Technology EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
-12.61 %+40,136.75%
-0.03 %-100.20%
15.59 %-340.06%
-6.49 %-79.86%
-32.25 %+53.67%
-20.99 %-1,139.53%
2.02 %-94.09%
34.15 %-117.78%
-192.13 %+52.23%
-126.21 %-34.43%
-192.48 %+749.91%
-22.65 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Bio-Gene Technology Stock analysis

What does Bio-Gene Technology do? Bio-Gene Technology Ltd develops and commercializes insecticides using beta-triketone platform technology. The company's lead products are Flavocide, a chemically synthesized insecticide based on flavesone, and Qcide, a natural oil product containing tasmanone extracted from Gympie Messmate leaves via steam distillation. These products address insecticide resistance and toxicity issues in crop protection, storage, public health, animal health, and consumer applications. Insecticide manufacturers purchase the company's platform technology and products for commercialization across multiple sectors. The firm's beta-triketone platform provides multiple solutions for insecticide manufacturers seeking to develop novel pest control products. Flavocide and Qcide represent the company's primary commercial offerings, with Flavocide targeting synthetic insecticide markets and Qcide focusing on natural oil-based solutions. The company's technology enables the development of targeted insect control solutions for various applications including agricultural crop protection and public health management. Bio-Gene Technology Ltd. aims to develop a portfolio of targeted insect control solutions for insecticide manufacturers. The company's platform technology allows manufacturers to create new products addressing resistance and toxicity challenges. Through its two lead products, the company provides both synthetic and natural options for the insecticide market, targeting manufacturers who seek innovative solutions for pest management across different industry segments. Bio-Gene Technology is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Bio-Gene Technology stock

Year-over-Year EBITDA Growth of Bio-Gene Technology is -12.61 % in 2026.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth Bio-Gene Technology since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's Bio-Gene Technology historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — Bio-Gene Technology

All Key Metrics — Bio-Gene Technology